JP2022507606A5 - - Google Patents

Info

Publication number
JP2022507606A5
JP2022507606A5 JP2021526724A JP2021526724A JP2022507606A5 JP 2022507606 A5 JP2022507606 A5 JP 2022507606A5 JP 2021526724 A JP2021526724 A JP 2021526724A JP 2021526724 A JP2021526724 A JP 2021526724A JP 2022507606 A5 JP2022507606 A5 JP 2022507606A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
cancer
methionine
glycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021526724A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022507606A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/061813 external-priority patent/WO2020102728A1/en
Publication of JP2022507606A publication Critical patent/JP2022507606A/ja
Publication of JP2022507606A5 publication Critical patent/JP2022507606A5/ja
Priority to JP2024141869A priority Critical patent/JP7900790B2/ja
Pending legal-status Critical Current

Links

JP2021526724A 2018-11-16 2019-11-15 Il-7タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法 Pending JP2022507606A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024141869A JP7900790B2 (ja) 2018-11-16 2024-08-23 Il-7タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862768355P 2018-11-16 2018-11-16
US62/768,355 2018-11-16
US201962826734P 2019-03-29 2019-03-29
US62/826,734 2019-03-29
US201962896484P 2019-09-05 2019-09-05
US62/896,484 2019-09-05
PCT/US2019/061813 WO2020102728A1 (en) 2018-11-16 2019-11-15 Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024141869A Division JP7900790B2 (ja) 2018-11-16 2024-08-23 Il-7タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法

Publications (2)

Publication Number Publication Date
JP2022507606A JP2022507606A (ja) 2022-01-18
JP2022507606A5 true JP2022507606A5 (cg-RX-API-DMAC7.html) 2022-12-07

Family

ID=68916552

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021526724A Pending JP2022507606A (ja) 2018-11-16 2019-11-15 Il-7タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法
JP2024141869A Active JP7900790B2 (ja) 2018-11-16 2024-08-23 Il-7タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024141869A Active JP7900790B2 (ja) 2018-11-16 2024-08-23 Il-7タンパク質と免疫チェックポイント阻害剤の組み合わせで腫瘍を治療する方法

Country Status (8)

Country Link
US (1) US20220008515A1 (cg-RX-API-DMAC7.html)
EP (1) EP3880231A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022507606A (cg-RX-API-DMAC7.html)
KR (1) KR20210093950A (cg-RX-API-DMAC7.html)
CN (1) CN113365650B (cg-RX-API-DMAC7.html)
AU (1) AU2019379325B2 (cg-RX-API-DMAC7.html)
CA (1) CA3119341A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020102728A1 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7102670B2 (ja) * 2018-01-25 2022-07-20 アイ-エムエービー バイオファーマ ユーエス リミテッド 抗pd‐l1抗体とil‐7との融合
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
CA3146948A1 (en) * 2019-09-04 2021-03-11 Young Chul Sung Method for increasing lymphocyte count by using il-7 fusion protein in tumors
WO2021245071A1 (en) * 2020-06-03 2021-12-09 Mv Biotherapeutics Sa Combination of an atp-hydrolyzing enzyme and an immune checkpoint modulator and uses thereof
EP4167889A4 (en) * 2020-06-19 2024-12-04 Grand Decade Developments Limited METHODS FOR DETERMINING RESPONSIVENESS TO CANCER IMMUNOTHERAPY
KR20230038496A (ko) * 2020-07-13 2023-03-20 트랜스진 면역 억제의 치료
JP2023549112A (ja) * 2020-11-05 2023-11-22 ネオイミューンテック, インコーポレイテッド Il-7タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
KR20240163103A (ko) 2022-03-10 2024-11-18 주식회사 제넥신 두경부암 치료를 위한 삼중 복합약물 투여요법
JP2026504619A (ja) * 2022-11-07 2026-02-06 ネオイミューンテック, インコーポレイテッド 非メチル化mgmtプロモーターを含む腫瘍を治療する方法
WO2024173571A1 (en) * 2023-02-14 2024-08-22 Amcyte Pharma, Inc. Interleukin formulations for in vivo use
JP2026508960A (ja) 2023-03-17 2026-03-13 クロジェン・テクノロジー・カンパニー・リミテッド 自己免疫疾患治療用新規融合タンパク質
CN121013867A (zh) * 2023-06-07 2025-11-25 Fbd生物制品有限公司 工程化的il-7变体及其使用方法

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
DK0482076T3 (da) 1989-07-14 1995-07-17 American Cyanamid Co Stabile vaccinepræparater indeholdende interleukiner
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
WO1994004196A1 (en) * 1992-08-14 1994-03-03 Imperial Cancer Research Technology Limited Tumour therapy
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
WO1998014179A1 (en) 1996-10-01 1998-04-09 Cima Labs Inc. Taste-masked microcapsule compositions and methods of manufacture
GB9621680D0 (en) 1996-10-17 1996-12-11 Oxford Biomedica Ltd Lentiviral vectors
PT904392E (pt) 1996-10-17 2001-06-29 Oxford Biomedica Ltd Vectores retrovirais
GB9622500D0 (en) 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6730512B2 (en) 1997-04-09 2004-05-04 Amdl, Inc. Combination immunogene therapy
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
CA2275539A1 (en) 1997-10-28 1999-05-06 Bando Chemical Industries, Ltd. A transdermal patch and a method for manufacture of a substrate sheet therefor
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
CA2343979C (en) 1998-09-21 2011-11-15 Schering Corporation Human interleukin-b50, therapeutic uses
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
MXPA02001878A (es) 1999-08-23 2003-08-20 Dana Farber Cancer Inst Inc Moleculas b7-4 novedosas y usos de las mismas.
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
US6749847B2 (en) 2000-03-30 2004-06-15 The University Of Connecticut Hybrid cytokine of IL-7 and β-chain of hepatocyte growth factor
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP1391513A1 (en) 2002-08-08 2004-02-25 Cytheris IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
US20050054054A1 (en) 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
KR101163424B1 (ko) 2003-12-30 2012-07-13 메르크 파텐트 게엠베하 Il-7 융합 단백질
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP1746161A1 (en) 2005-07-20 2007-01-24 Cytheris Glycosylated IL-7, preparation and uses
GB2434578A (en) 2006-01-26 2007-08-01 Univ Basel Transgenic animals
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
CN101687933B (zh) 2007-05-30 2015-11-25 浦项工科大学校产学协力团 免疫球蛋白融合蛋白
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
GB0815216D0 (en) 2008-08-21 2008-09-24 Asterion Ltd Interleukin
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
KR20130070576A (ko) 2010-04-09 2013-06-27 노보자임스 바이오파마 디케이 에이/에스 알부민 유도체 및 변이체
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
ES2699965T3 (es) 2011-03-10 2019-02-13 Provectus Pharmatech Inc Una combinación de rosa de bengala y anticuerpo anti-CTLA4 para su uso en el tratamiento del cáncer
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
DK3303394T3 (da) 2015-05-29 2020-07-06 Agenus Inc Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf
HK1256149A1 (zh) * 2015-06-11 2019-09-13 格纳西尼有限公司 经修饰的白细胞介素-7蛋白及其用途
US20190358258A1 (en) 2015-10-09 2019-11-28 Robert J. Deans Methods for enhancing proliferation of t regulatory cells
KR102386735B1 (ko) 2015-11-06 2022-04-14 주식회사 제넥신 변형된 인터루킨-7 융합 단백질의 제형
SG10201913538VA (en) * 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
EP3402508A4 (en) * 2016-01-11 2019-09-25 Flagship Pioneering Innovations V, Inc. METHOD AND COMPOSITIONS FOR MODULATING THE THYMUS FUNCTION
US20190060286A1 (en) * 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
TWI822521B (zh) * 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
FI3922279T3 (fi) * 2016-08-30 2025-02-04 Dana Farber Cancer Inst Inc Lääkkeenantokoostumuksia ja niiden käyttötapoja
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
WO2018215937A1 (en) * 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer

Similar Documents

Publication Publication Date Title
JP7358365B2 (ja) がんを治療するための、化学療法剤と併用した多量体抗dr5結合分子の使用
US11905322B2 (en) Engineered PD-1 variants
JP2022527635A5 (cg-RX-API-DMAC7.html)
CN108463469B (zh) 一种与抗可替宁抗体连接的嵌合抗原受体及其用途
JP2019526578A (ja) キャリアー−pd−l1結合剤組成物及び癌を処置する為にそれを使用する方法
JP2009526010A5 (cg-RX-API-DMAC7.html)
MX2014007121A (es) Nuevos conjugados de principio activo-ligante (adc) y su uso.
JP2020521478A5 (cg-RX-API-DMAC7.html)
JP2021533789A5 (cg-RX-API-DMAC7.html)
WO2016145030A1 (en) Compositions and methods for enhancing the efficacy of cancer therapy
KR20230010221A (ko) 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도
JP2021526377A5 (cg-RX-API-DMAC7.html)
CN114746116A (zh) 用于免疫疗法的组合物和方法
WO2025067400A1 (en) Combination of anti-claudin 18.2/anti-4-1bb antibodies and second therapeutic agent in treatment of cancer
KR20250028265A (ko) 항체 및 이의 용도
TW202400246A (zh) 免疫調節抗體-藥物結合物
CA3230737A1 (en) Pharmaceutical composition for cancer treatment and/or prevention
WO2024148339A1 (en) Use of a multimeric anti-dr5 antibody for treating cancer
JP2023516089A (ja) がんの治療のための組成物及び方法
JP2023512456A5 (cg-RX-API-DMAC7.html)
JP2025517656A5 (cg-RX-API-DMAC7.html)
JP2025509401A (ja) 頭頸部がん治療のための三重複合薬物投与療法
WO2008037225A1 (es) Composiciones terapéuticas para potenciar el efecto de la terapia con anticuerpos contra el receptor del factor de crecimiento epidérmico
EP4722240A1 (en) Combination of antibodies, or antigen-binding fragments thereof, for the treatment of cancers and compositions thereof
US20250025553A1 (en) Combination therapy for cancer